Human mesenchymal stem cells exert potent antitumorigenic effects in a model of Kaposi's sarcoma

Journal of Experimental Medicine

Volumn 203, Issue 5, 2006, Pages 1235-1247

  Khakoo, Aarif Y ^a,f   Pati, Shibani ^d,e   Anderson, Stasia A ^c   Reid, William ^d,e   Elshal, Mohamed F ^a   Rovira, Ilsa I ^a   Nguyen, Ahn T ^d,e   Malide, Daniela ^a   Combs, Christian A ^a   Hall, Gentzon ^e   Zhang, Jianhu ^f   Raffeld, Mark ^b   Rogers, Terry B ^e   Stetler Stevenson, William ^b   Frank, Joseph A ^c   Reitz, Marvin ^d,e   Finkel, Toren ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c NATIONAL INSTITUTES OF HEALTH   (United States)

^d INSTITUTE OF HUMAN VIROLOGY   (United States)

^e UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B; UVOMORULIN;

ARTICLE; CANCER INHIBITION; CARCINOGENESIS; CELL CULTURE; CELL INFILTRATION; CELL INTERACTION; CONTROLLED STUDY; DOWN REGULATION; ENZYME ACTIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KAPOSI SARCOMA; MESENCHYMAL STEM CELL; MESENCHYMAL STEM CELL TRANSPLANTATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TARGET CELL;

ANIMALS; DISEASE MODELS, ANIMAL; ENZYME ACTIVATION; GRAFT VS TUMOR EFFECT; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STEM CELLS; MICE; MICE, NUDE; NEOPLASM TRANSPLANTATION; NEOPLASMS, EXPERIMENTAL; ONCOGENE PROTEIN V-AKT; SARCOMA, KAPOSI; STROMAL CELLS; TRANSPLANTATION, HETEROLOGOUS; TUMOR CELLS, CULTURED;

EID: 33646690027     PISSN: 00221007     EISSN: 00221007     Source Type: Journal    
DOI: 10.1084/jem.20051921     Document Type: Article

References (60)

1. Archuleta, T.D., M.P. Devetten, and J.O. Armitage. 2004. Hematopoietic stem cell transplantation in hematologic malignancy. Panminerva Med. 46:61-74.
2. Gardner, S.L. 2004. Application of stem cell transplant for brain tumors. Pediatr. Transplant. 8:28-32.
3. Smalley, M., and A. Ashworth. 2003. Stem cells and breast cancer: A field in transit. Nat. Rev. Cancer. 3:832-844.
4. Scadden, D.T. 2004. Cancer stem cells refined. Nat. Immunol. 5: 701-703.
5. Reya, T., S.J. Morrison, M.F. Clarke, and I.L. Weissman. 2001. Stem cells, cancer, and cancer stem cells. Nature. 414:105-111.
6. Sell, S. 2004. Stem cell origin of cancer and differentiation therapy. Crit. Rev. Oncol. Hematol. 51:1-28.
7. Bhowmick, N.A., E.G. Neilson, and H.L. Moses. 2004. Stromal fibroblasts in cancer initiation and progression. Nature. 432:332-337.
8. Bhowmick, N.A., A. Chytil, D. Plieth, A.E. Gorska, N. Dumont, S. Shappell, M.K. Washington, E.G. Neilson, and H.L. Moses. 2004. TGF-beta signaling in fibroblasts modulates the oncogenic potential of adjacent epithelia. Science. 303:848-851.
9. Orimo, A., P.B. Gupta, D.C. Sgroi, F. Arenzana-Seisdedos, T. Delaunay, R. Naeem, V.J. Carey, A.L. Richardson, and R.A. Weinberg. 2005. Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1/CXCL12 secretion. Cell. 121:335-348.
10. Barcellos-Hoff, M.H., and S.A. Ravani. 2000. Irradiated mammary gland stroma promotes the expression of tumorigenic potential by unirradiated epithelial cells. Cancer Res. 60:1254-1260.
11. Olumi, A.F., G.D. Grossfeld, S.W. Hayward, P.R. Carroll, T.D. Tlsty, and G.R. Cunha. 1999. Carcinoma-associated fibroblasts direct tumor progression of initiated human prostatic epithelium. Cancer Res. 59:5002-5011.
12. Javazon, E.H., K.J. Beggs, and A.W. Flake. 2004. Mesenchymal stem cells: paradoxes of passaging. Exp. Hematol. 32:414-425.
13. Pittenger, M.F., A.M. Mackay, S.C. Beck, R.K. Jaiswal, R. Douglas, J.D. Mosca, M.A. Moorman, D.W. Simonetti, S. Craig, and D.R. Marshak. 1999. Multilineage potential of adult human mesenchymal stem cells. Science. 284:143-147.
14. Hamada, H., M. Kobune, K. Nakamura, Y. Kawano, K. Kato, O. Honmou, K. Houkin, T. Matsunaga, and Y. Niitsu. 2005. Mesenchymal stem cells (MSC) as therapeutic cytoreagents for gene therapy. Cancer Sci. 96:149-156.
15. Chen, J., Y. Li, L. Wang, Z. Zhang, D. Lu, M. Lu, and M. Chopp. 2001. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 32:1005-1011.
16. Barbash, I.M., P. Chouraqui, J. Baron, M.S. Feinberg, S. Etzion, A. Tessone, L. Miller, E. Guetta, D. Zipori, L.H. Kedes, et al. 2003. Systemic delivery of bone marrow-derived mesenchymal stem cells to the infarcted myocardium: feasibility, cell migration, and body distribution. Circulation. 108:863-868.
17. Le Blanc, K., C. Tammik, K. Rosendahl, E. Zetterberg, and O. Ringden. 2003. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31:890-896.
18. Aggarwal, S., and M.F. Pittenger. 2004. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood. 105:1815-1822.
19. Djouad, F., P. Plence, C. Bony, P. Tropel, F. Apparailly, J. Sany, D. Noel, and C. Jorgensen. 2003. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood. 102:3837-3844.
20. Pittenger, M.F., and B.J. Martin. 2004. Mesenchymal stem cells and their potential as cardiac therapeutics. Circ. Res. 95:9-20.
21. Studeny, M., F.C. Marini, J.L. Dembinski, C. Zompetta, M. Cabreira-Hansen, B.N. Bekele, R.E. Champlin, and M. Andreeff. 2004. Mesenchymal stem cells: potential precursors for tumor stroma and targeted-delivery vehicles for anticancer agents. J. Natl. Cancer Inst. 96:1593-1603.
22. Cheung, T.W. 2004. AIDS-related cancer in the era of highly active antiretroviral therapy (HAART): a model of the interplay of the immune system, virus, and cancer. "On the offensive-the Trojan Horse is being destroyed"-Part A: Kaposi's sarcoma. Cancer Invest. 22:774-786.
23. Reitz, M.S., Jr., L.S. Nerurkar, and R.C. Gallo. 1999. Perspective on Kaposi's sarcoma: facts, concepts, and conjectures. J. Natl. Cancer Inst. 91:1453-1458.
24. Ensoli, B., and M. Sturzl. 1998. Kaposi's sarcoma: a result of the interplay among inflammatory cytokines, angiogenic factors and viral agents. Cytokine Growth Factor Rev. 9:63-83.
25. Moore, P.S., L.A. Kingsley, S.D. Holmberg, T. Spira, P. Gupta, D.R. Hoover, J.P. Parry, L.J. Conley, H.W. Jaffe, and Y. Chang. 1996. Kaposi's sarcoma-associated herpesvirus infection prior to onset of Kaposi's sarcoma. AIDS. 10:175-180.
26. Chang, Y., E. Cesarman, M.S. Pessin, F. Lee, J. Culpepper, D.M. Knowles, and P.S. Moore. 1994. Identification of herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 266:1865-1869.
27. Serakinci, N., P. Guldberg, J.S. Burns, B. Abdallah, H. Schrodder, T. Jensen, and M. Kassem. 2004. Adult human mesenchymal stem cell as a target for neoplastic transformation. Oncogene. 23:5095-5098.
28. Houghton, J., C. Stoicov, S. Nomura, A.B. Rogers, J. Carlson, H. Li, X. Cai, J.G. Fox, J.R. Goldenring, and T.C. Wang. 2004. Gastric cancer originating from bone marrow-derived cells. Science. 306:1568-1571.
29. Kinnaird, T., E. Stabile, M.S. Burnett, M. Shou, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein. 2004. Local delivery of marrow-derived stromal cells augments collateral perfusion through paracrine mechanisms. Circulation. 109:1543-1549.
30. Kinnaird, T., E. Stabile, M.S. Burnett, C.W. Lee, S. Barr, S. Fuchs, and S.E. Epstein. 2004. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ. Res. 94:678-685.
31. Al-Khaldi, A., H. Al-Sabti, J. Galipeau, and K. Lachapelle. 2003. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann. Thorac. Surg. 75:204-209.
32. Nakamura, K., Y. Ito, Y. Kawano, K. Kurozumi, M. Kobune, H. Tsuda, A. Bizen, O. Honmou, Y. Niitsu, and H. Hamada. 2004. Antitumor effect of genetically engineered mesenchymal stem cells in a rat glioma model. Gene Ther. 11:1155-1164.
33. Arbab, A.S., G.T. Yocum, H. Kalish, E.K. Jordan, S.A. Anderson, A.Y. Khakoo, E.J. Read, and J.A. Frank. 2004. Efficient magnetic cell labeling with protamine sulfate complexed to ferumoxides for cellular MRI. Blood. 104:1217-1223.
34. Arbab, A.S., L.A. Bashaw, B.R. Miller, E.K. Jordan, B.K. Lewis, H. Kalish, and J.A. Frank. 2003. Characterization of biophysical and metabolic properties of cells labeled with superparamagnetic iron oxide nanoparticles and transfection agent for cellular MR imaging. Radiology. 229:838-846.
35. Gullino, P.M. 1976. In vivo utilization of oxygen and glucose by neoplastic tissue. Adv. Exp. Med. Biol. 75:521-536.
36. Kwon, S.J., and Y.J. Lee. 2005. Effect of low glutamine/glucose on hypoxia-induced elevation of hypoxia-inducible factor-1alpha in human pancreatic cancer MiaPaCa-2 and human prostatic cancer DU-145 cells. Clin. Cancer Res. 11:4694-4700.
37. Pati, S., M. Cavrois, H.G. Guo, J.S. Foulke Jr., J. Kim, R.A. Feldman, and M. Reitz. 2001. Activation of NF-kappaB by the human herpesvirus 8 chemokine receptor ORF74: evidence for a paracrine model of Kaposi's sarcoma pathogenesis. J. Virol. 75:8660-8673.
38. Sodhi, A., S. Montaner, V. Patel, J.J. Gomez-Roman, Y. Li, E.A. Sausville, E.T. Sawai, and J.S. Gutkind. 2004. Akt plays a central role in sarcomagenesis induced by Kaposi's sarcoma herpesvirus-encoded G protein-coupled receptor. Proc. Natl. Acad. Sci. USA. 101:4821-4826.
39. Beyth, S., Z. Borovsky, D. Mevorach, M. Liebergall, Z. Gazit, H. Aslan, E. Galun, and J. Rachmilewitz. 2005. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T cell unresponsiveness. Blood. 105:2214-2219.
40. Glennie, S., I. Soeiro, P.J. Dyson, E.W. Lam, and F. Dazzi. 2005. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood. 105:2821-2827.
41. Birchmeier, W., K.M. Weidner, J. Hulsken, and J. Behrens. 1993. Molecular mechanisms leading to cell junction (cadherin) deficiency in invasive carcinomas. Semin. Cancer Biol. 4:231-239.
42. Bosch, F.X., C. Andl, U. Abel, and J. Kartenbeck. 2005. E-cadherin is a selective and strongly dominant prognostic factor in squamous cell carcinoma: a comparison of E-cadherin with desmosomal components. Int. J. Cancer. 114:779-790.
43. Motti, M.L., D. Califano, G. Baldassarre, A. Celetti, F. Merolla, F. Forzati, M. Napolitano, B. Tavernise, A. Fusco, and G. Viglietto. 2005. Reduced E-cadherin expression contributes to the loss of p27kip1-mediated mechanism of contact inhibition in thyroid anaplastic carcinomas. Carcinogenesis. 26:1021-1034.
44. Pecina-Slaus, N. 2003. Tumor suppressor gene E-cadherin and its role in normal and malignant cells. Cancer Cell Int. 3:17.
45. Mangi, A.A., N. Noiseux, D. Kong, H. He, M. Rezvani, J.S. Ingwall, and V.J. Dzau. 2003. Mesenchymal stem cells modified with Akt prevent remodeling and restore performance of infarcted hearts. Nat. Med. 9:1195-1201.
46. Shake, J.G., P.J. Gruber, W.A. Baumgartner, G. Senechal, J. Meyers, J.M. Redmond, M.F. Pittenger, and B.J. Martin. 2002. Mesenchymal stem cell implantation in a swine myocardial infarct model: engraftment and functional effects. Ann. Thorac. Surg. 73:1919-1925.
47. van Empel, V.P., and L.J. De Windt. 2004. Myocyte hypertrophy and apoptosis: a balancing act. Cardiovasc. Res. 63:487-499.
48. Matsui, T., L. Li, J.C. Wu, S.A. Cook, T. Nagoshi, M.H. Picard, R. Liao, and A. Rosenzweig. 2002. Phenotypic spectrum caused by transgenic overexpression of activated Akt in the heart. J. Biol. Chem. 277:22896-22901.
49. Dudek, H., S.R. Datta, T.F. Franke, M.J. Birnbaum, R. Yao, G.M. Cooper, R.A. Segal, D.R. Kaplan, and M.E. Greenberg. 1997. Regulation of neuronal survival by the serine-threonine protein kinase Akt. Science. 275:661-665.
50. Prockop, D.J. 1997. Marrow stromal cells as stem cells for nonhematopoietic tissues. Science. 276:71-74.
51. Singh, S.K., I.D. Clarke, M. Terasaki, V.E. Bonn, C. Hawkins, J. Squire, and P.B. Dirks. 2003. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63:5821-5828.
52. Nagaya, N., T. Fujii, T. Iwase, H. Ohgushi, T. Itoh, M. Uematsu, M. Yamagishi, H. Mori, K. Kangawa, and S. Kitamura. 2004. Intravenous administration of mesenchymal stem cells improves cardiac function in rats with acute myocardial infarction through angiogenesis and myogenesis. Am. J. Physiol. Heart Circ. Physiol. 287:H2670-H2676.
53. Tang, Y.L., Q. Zhao, X. Qin, L. Shen, L. Cheng, J. Ge, and M.I. Phillips. 2005. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann. Thorac. Surg. 80:229-236.
54. Lazarus, H.M., O.N. Koc, S.M. Devine, P. Curtin, R.T. Maziarz, H.K. Holland, E.J. Shpall, P. McCarthy, K. Atkinson, B.W. Cooper, et al. 2005. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11:389-398.
55. Maitra, B., E. Szekely, K. Gjini, M.J. Laughlin, J. Dennis, S.E. Haynesworth, and O.N. Koc. 2004. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33:597-604.
56. Le Blanc, K., and O. Ringden. 2005. Immunobiology of human mesenchymal stem cells and future use in hematopoietic stem cell transplantation. Biol. Blood Marrow Transplant. 11:321-334.
57. Mintz, B., and K. Illmensee. 1975. Normal genetically mosaic mice produced from malignant teratocarcinoma cells. Proc. Natl. Acad. Sci. USA. 72:3585-3589.
58. Braun, A.C., and H.N. Wood. 1976. Suppression of the neoplastic state with the acquisition of specialized functions in cells, tissues, and organs of crown gall teratomas of tobacco. Proc. Natl. Acad. Sci. USA. 73: 496-500.
59. Albini, A., I. Paglieri, G. Orengo, S. Carlone, M.G. Aluigi, R. DeMarchi, C. Matteucci, A. Mantovani, F. Carozzi, S. Donini, and R. Benelli. 1997. The beta-core fragment of human chorionic gonadotrophin inhibits growth of Kaposi's sarcoma-derived cells and a new immortalized Kaposi's sarcoma cell line. AIDS. 11:713-721.
60. Hall, G., I.S. Singh, L. Hester, J.D. Hasday, and T.B. Rogers. 2005. Inhibitor-kappaB kinase-beta regulates LPS-induced TNF-alpha production in cardiac myocytes through NF-kappaB p65 subunit phosphorylation. Am. J. Physiol. Heart Circ. Physiol. 289:H2103-H2111.